Sofia Bengtzén

672 total citations
20 papers, 496 citations indexed

About

Sofia Bengtzén is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Sofia Bengtzén has authored 20 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 14 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Sofia Bengtzén's work include Acute Myeloid Leukemia Research (16 papers), Epigenetics and DNA Methylation (5 papers) and Retinoids in leukemia and cellular processes (4 papers). Sofia Bengtzén is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Epigenetics and DNA Methylation (5 papers) and Retinoids in leukemia and cellular processes (4 papers). Sofia Bengtzén collaborates with scholars based in Sweden, Germany and United States. Sofia Bengtzén's co-authors include Christer Paul, Sören Lehmann, Hareth Nahi, Stefan Deneberg, Lars Möllgård, Mats Merup, Klas G. Wiman, Andreas Lennartsson, Galina Selivanova and Ying Qu and has published in prestigious journals such as Blood, British Journal of Haematology and Genome Medicine.

In The Last Decade

Sofia Bengtzén

19 papers receiving 490 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sofia Bengtzén Sweden 13 362 227 146 103 81 20 496
Anuradha Illendula United States 10 317 0.9× 191 0.8× 87 0.6× 44 0.4× 35 0.4× 19 435
Katherine Knorr United States 7 424 1.2× 83 0.4× 94 0.6× 118 1.1× 50 0.6× 9 529
Nandini Ramachandra United States 8 241 0.7× 123 0.5× 112 0.8× 68 0.7× 38 0.5× 15 450
Florian Perner Germany 10 293 0.8× 238 1.0× 64 0.4× 47 0.5× 124 1.5× 26 471
Ernest Medina United States 6 444 1.2× 89 0.4× 160 1.1× 80 0.8× 34 0.4× 9 607
Swathi-Rao Narayanagari United States 4 194 0.5× 200 0.9× 58 0.4× 45 0.4× 61 0.8× 4 374
Soraya Wuillème‐Toumi France 5 467 1.3× 230 1.0× 151 1.0× 48 0.5× 37 0.5× 6 553
Le Xuan Truong Nguyen United States 12 319 0.9× 101 0.4× 81 0.6× 82 0.8× 27 0.3× 30 416
Véronique Mansat‐De Mas France 7 308 0.9× 129 0.6× 107 0.7× 35 0.3× 39 0.5× 7 391
Anna Krug United States 6 538 1.5× 426 1.9× 83 0.6× 244 2.4× 63 0.8× 10 739

Countries citing papers authored by Sofia Bengtzén

Since Specialization
Citations

This map shows the geographic impact of Sofia Bengtzén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Bengtzén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Bengtzén more than expected).

Fields of papers citing papers by Sofia Bengtzén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Bengtzén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Bengtzén. The network helps show where Sofia Bengtzén may publish in the future.

Co-authorship network of co-authors of Sofia Bengtzén

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Bengtzén. A scholar is included among the top collaborators of Sofia Bengtzén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Bengtzén. Sofia Bengtzén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhong, Xiangfu, Lina Cordeddu, Sofia Bengtzén, et al.. (2025). Disease-specific epigenetic deregulation of enhancers, transposons, and polycomb targets in acute promyelocytic leukemia. Genome Medicine. 17(1). 135–135.
2.
Vesterlund, Mattias, Tojo James, Georgios Mermelekas, et al.. (2024). Delineating functional and molecular impact of ex vivo sample handling in precision medicine. npj Precision Oncology. 8(1). 38–38. 2 indexed citations
3.
Bengtzén, Sofia, Sören Lehmann, Olli Kallioniemi, et al.. (2022). Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing. Blood. 140(Supplement 1). 6290–6290. 1 indexed citations
4.
Mareschal, Sylvain, Anna Palau, Johan Lindberg, et al.. (2021). Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Advances. 5(4). 1003–1016. 12 indexed citations
5.
Bengtzén, Sofia, Christer Nilsson, Stefan Deneberg, et al.. (2020). AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding. Blood. 136(3). 339–352. 12 indexed citations
6.
Qu, Ying, Andreas Lennartsson, Verena I. Gaidzik, et al.. (2014). Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated byDNMT3Amutational status and associated with predominant hypomethylation of HOX genes. Epigenetics. 9(8). 1108–1119. 65 indexed citations
7.
Deneberg, Stefan, Meena Kanduri, Dina Ali, et al.. (2014). microRNA-34b/con chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics. 9(6). 910–917. 42 indexed citations
8.
9.
Deneberg, Stefan, Philippe Guardiola, Andreas Lennartsson, et al.. (2011). Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood. 118(20). 5573–5582. 61 indexed citations
10.
Ali, Dina, Stefan Deneberg, Sofia Bengtzén, et al.. (2010). APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. European Journal Of Haematology. 86(3). 206–215. 53 indexed citations
11.
Uggla, Bertil, Stefan Deneberg, Sofia Bengtzén, et al.. (2009). Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leukemia & lymphoma. 50(9). 1512–1518. 4 indexed citations
12.
Nahi, Hareth, Sören Lehmann, Sofia Bengtzén, et al.. (2008). Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leukemia & lymphoma. 49(3). 508–516. 26 indexed citations
13.
Nahi, Hareth, Galina Selivanova, Sören Lehmann, et al.. (2008). Mutated and non‐mutated TP53 as targets in the treatment of leukaemia. British Journal of Haematology. 141(4). 445–453. 42 indexed citations
14.
Deneberg, Stefan, Michael Grövdal, Monika Jansson, et al.. (2008). Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.. Blood. 112(11). 3337–3337. 1 indexed citations
15.
Möllgård, Lars, Stefan Deneberg, Hareth Nahi, et al.. (2007). The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 62(3). 439–448. 28 indexed citations
16.
Nahi, Hareth, Mats Merup, Sören Lehmann, et al.. (2005). PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. British Journal of Haematology. 132(2). 230–236. 47 indexed citations
17.
Nahi, Hareth, Sören Lehmann, Lars Möllgård, et al.. (2004). Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. British Journal of Haematology. 127(3). 285–291. 49 indexed citations
18.
Möllgård, Lars, Sofia Bengtzén, Thoas Fioretos, et al.. (2004). Effects of the FLT3 Inhibitor PKC 412 in Combination with Cytostatic Drugs In Vitro in Acute Myeloid Leukemia.. Blood. 104(11). 1810–1810. 2 indexed citations
19.
20.
Lehmann, Sylvain, et al.. (2000). Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. Leukemia Research. 24(1). 19–25. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anuradha Illendula Breakdown of academic impact, for papers by Katherine Knorr Breakdown of academic impact, for papers by Nandini Ramachandra Breakdown of academic impact, for papers by Florian Perner Breakdown of academic impact, for papers by Ernest Medina Breakdown of academic impact, for papers by Swathi-Rao Narayanagari Breakdown of academic impact, for papers by Soraya Wuillème‐Toumi Breakdown of academic impact, for papers by Le Xuan Truong Nguyen Breakdown of academic impact, for papers by Véronique Mansat‐De Mas Breakdown of academic impact, for papers by Anna Krug
Rankless by CCL
2026